Mink therapeutics reports fourth quarter and full year 2022 financial results

New york, march 21, 2023 (globe newswire) -- mink therapeutics, inc. (nasdaq: inkt), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer t (inkt) cell therapies to treat cancer and other immune-mediated diseases, today reported financial results for the fourth quarter and full year 2022.
INKT Ratings Summary
INKT Quant Ranking